Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
26 févr. 2024 08h30 HE
|
Ocugen
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
22 févr. 2024 16h05 HE
|
Ocugen
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Global Advanced Therapy Medicinal Products CDMO Market Analysis Report 2024-2030: : Increasing Investment and Clinical Trial Expenditure Driving Demand, Oncology Dominance and Emerging Treatment Areas
22 févr. 2024 06h42 HE
|
Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase,...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
14 févr. 2024 07h30 HE
|
Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
12 févr. 2024 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
UK Cell & Gene Therapy Cold Chain Logistics Market Analysis to 2028: Dominated by Atelerix, Life Science Group, and Cryoport UK
08 févr. 2024 09h56 HE
|
Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "United Kingdom Cell & Gene Therapy Cold Chain Logistics Market, Competition, Forecast & Opportunities, 2028" report has been added to ...
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
08 févr. 2024 07h00 HE
|
Adverum Biotechnologies, Inc.
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and...
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
08 févr. 2024 05h00 HE
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
Advanced Therapy Medicinal Products Market to Accumulate a Valuation of USD 61.5 Billion by 2030, Advancing at a 13.4% CAGR | MarketDigits
06 févr. 2024 07h15 HE
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to a research report "Advanced Therapy Medicinal Products Market”, by Therapy Type (Cell Therapy {Stem Cell Therapy, Non-stem Cell Therapy},...
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
05 févr. 2024 07h45 HE
|
Adverum Biotechnologies, Inc.
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare...